SWOG clinical trial number

SWOG-8954

Evaluation of the L-17M Protocol in the Management of Patients with Lymphoblastic Lymphoma

Closed

Phase

Accrual

74%

Abbreviated Title

Evaluation of the L-17M Protocol in the Management of Patients with Lymphoblastic Lymphoma

Activated

04/15/1990

Closed

05/15/1997

Research committees

Lymphoma

Other Clinical Trials

SWOG Clinical Trial Number

S2506

MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma

Research Committee(s)

Lymphoma

Activated

08/18/2026

Accrual

0%

Open

Phase

SWOG Clinical Trial Number

CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Research Committee(s)

Lymphoma

Activated

01/30/2025

Open

Phase

SWOG Clinical Trial Number

S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)

Lymphoma

Activated

08/01/2024

Accrual

69%

Open

Phase